Search results (1320)
« Back to PublicationsBYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Juric D. et al, (2012), CANCER RESEARCH, 72
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate.
Khan OA. et al, (2012), Br J Cancer, 106
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
Khan OA. et al, (2012), British Journal of Cancer, 106
A study of symptoms described by ovarian cancer survivors.
Stavraka C. et al, (2012), Gynecol Oncol, 125, 59 - 64
Germline activating JAK2-mutation in a family with hereditary thrombocytosis
Mead A. et al, (2012), BRITISH JOURNAL OF HAEMATOLOGY, 157, 21 - 21
Germline JAK2 mutation in a family with hereditary thrombocytosis.
Mead AJ. et al, (2012), N Engl J Med, 366, 967 - 969
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
Patterson DM. et al, (2012), Clin Cancer Res, 18, 1415 - 1425
Pulmonary nodules in patients with melanoma--assume nothing.
Murphy F. et al, (2012), Ann Oncol, 23, 545 - 546
Tumor refractoriness to anti-VEGF therapy is mediated by myeloid cell recruitment in malignant melanoma
Helfrich I. et al, (2012), EXPERIMENTAL DERMATOLOGY, 21, e45 - e45
The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.
Luc S. et al, (2012), Nat Immunol, 13, 412 - 419
Megakaryocytes, malignancy and bone marrow vascular niches.
Psaila B. et al, (2012), J Thromb Haemost, 10, 177 - 188
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Gillies RS. et al, (2012), Br J Surg, 99, 239 - 245
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Dean E. et al, (2012), Br J Cancer, 106, 468 - 474
New challenges in endpoints for drug development in advanced melanoma.
Ribas A. et al, (2012), Clin Cancer Res, 18, 336 - 341
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM. et al, (2012), Clin Cancer Res, 18, 555 - 567
Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.
Li HK. et al, (2012), J Clin Oncol, 30, e19 - e20
Epithelial Ovarian Cancer
Gabra H. and Blagden S., (2012), Dewhurst's Textbook of Obstetrics & Gynaecology: Eighth Edition, 760 - 775
LARP1 Regulates the Site-specific Synthesis of Proteins Required for Cancer Cell Invasion and Migration
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, S77 - S77
Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
Soria JC. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 188 - 188